Clinical trials: Unresectable Colorectal Carcinoma
Solid Tumors, Neoplasms (Cancer / Tumors)
Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor
The goal of this clinical trial is to learn if Trastuzumab Rezetecan can treat advanced solid tumors with HER-2 expression in adult participants.
- Conditions
- Solid Tumors, Neoplasms (Cancer / Tumors), Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid Neoplasm
- Trial name
- NCT07631884
- Testing
- Trastuzumab Rezetecan
- Volunteers
- 15 people
- Sponsor
- Haihua Yuan
Advanced Colorectal Carcinoma, Liver Metastasis Colon Cancer
Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy
Fruquintinib (HMPL-013) is a novel oral small molecule that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts.
- Trial name
- NCT05406206
- Testing
- Fruquintinib, Hepatic Arterial Infusion Chemotherapy
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Peking University Cancer Hospital & Institute
Unresectable Colorectal Liver Metastases
Local Immunomodulation After Radiofrequency of Unresectable Colorectal Liver Metastases
The main objective of this trial is to determine feasibility and tolerance of the human body to RFA associated with local immunomodulation carried out using a thermoreversible hydrogel combined with 2 immunomodulators, GMCSF and…
- Trial name
- LICoRN-01 (NCT04062721)
- Testing
- Chemotherapy, Radiofrequency ablation (RFA), In situ immunotherapy
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Colorectal Cancer
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma
This study is being done to answer the main question of: Do patients with colorectal cancer that cannot be removed by surgery, that is treated with two new immunotherapy drugs, botensilimab and balstilimab, live longer? Other…
- Trial name
- BATTMAN (NCT07152821)
- Testing
- Best Supportive Care, Balstilimab, Botensilimab
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- Canadian Cancer Trials Group
Metastatic Colorectal Cancer (CRC)
A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer
This study is a prospective, single-arm, multicenter exploratory clinical study aimed at evaluating the efficacy and safety of iparomlimab and tuvonralimab combined with bevacizumab and alternating triweekly CAPOX/mCAPIRI regimen…
- Trial name
- NCT07446387
- Testing
- Iparomlimab and tuvonralimab
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Unresectable Colorectal Cancer, Metastatic Colorectal Cancer (CRC)
QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC
This is a single-arm, multi-center, exploratory study evaluating the efficacy and safety of iparomlimab and tuvonralimab (QL1706) in combination with bevacizumab for the treatment of patients with microsatellite instability-high…
- Conditions
- Unresectable Colorectal Cancer, Metastatic Colorectal Cancer (CRC), MSI-H/dMMR Colorectal Cancer
- Trial name
- NCT07009145
- Testing
- QL1706, Bevacizumab
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Qianfoshan Hospital
Colorectal Cancer Metastatic
Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
To evaluate the efficacy and safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic…
- Trial name
- NCT06282445
- Testing
- Adebrelimab, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Anal Cancer
A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma
SCARCE is a non-comparative randomized, 2:1 phase II study. The purpose of this study is to assess the progression-free survival rate at 12 months. (evaluation according with RECISTv1.1 criteria).
- Trial name
- SCARCE (NCT03519295)
- Testing
- MPDL3280A, mDCF
- Where
- 31 sites in France
- Volunteers
- 97 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Unresectable Metastatic Colorectal Cancer, Unresectable Locally Advanced Colorectal Cancer
First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer
This is a phase I/IIA, first-in-human (FIH), two-part, open-label, multicenter study to characterize the safety, tolerability profile, and clinical efficacy of STC-1010 associated with GM-CSF and cyclophosphamide immunostimulant…
- Trial name
- NCT06934538
- Testing
- STC-1010 + IS regimen + SOC therapy
- Where
- 9 sites in United States, Belgium and 1 more
- Volunteers
- 90 people
- Sponsor
- Brenus Pharma
Advanced Solid Tumor, Unresectable Solid Tumor
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma
- Trial name
- GUARDIAN-101 (NCT06778863)
- Testing
- CLSP-1025
- Where
- 21 sites in United States
- Volunteers
- 90 people
- Sponsor
- Clasp Therapeutics, Inc.
Colorectal Neoplasms
TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has Spread
This study will assess the safety and anticancer activity of TQB2922 injection given under the skin together with chemotherapy in adults with colorectal cancer that has spread, cannot be removed by surgery, and has no RAS or BRAF…
- Trial name
- NCT07844187
- Testing
- TQB2922 injection (subcutaneous administration), Oxaliplatin, Calcium folinate (leucovorin calcium)
- Where
- 16 sites in China
- Volunteers
- 64 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Colorectal Carcinoma
Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma
The purpose of this study is to exploratorily examine efficacy and safety in the participants with chemotherapy-naïve unresectable, advanced/recurrent colorectal carcinoma of Kirsten rat sarcoma-2 virus (KRAS) wild-type who have…
- Trial name
- SAPPHIRE (NCT02337946)
- Testing
- oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
- Where
- 49 sites in Japan
- Volunteers
- 164 people
- Sponsor
- Takeda
Adult Solid Neoplasm, Bladder Carcinoma
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
This phase I trial studies the side effects of vaccine therapy and pembrolizumab in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment, that…
- Conditions
- Adult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma, Estrogen Receptor Negative
- Trial name
- NCT02432963
- Testing
- Laboratory Biomarker Analysis, Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- City of Hope Medical Center
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors.
- Trial name
- NCT07488676
- Testing
- ASP546C
- Where
- 21 sites in United States, Japan
- Volunteers
- 150 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Colorectal Cancer, Liver Metastases
Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)
General Objectives: To test the feasibility of neoadjuvant treatment with cetuximab/chemotherapy followed by liver resection To determine the optimal combination (cetuximab/FOLFOX versus cetuximab/FOLFIRI) for further trials in…
- Trial name
- NCT00153998
- Testing
- Cetuximab, Liver resection, Cetuximab and FOLFIRI
- Where
- 21 sites in Austria, Germany
- Volunteers
- 135 people
- Sponsor
- Technische Universität Dresden
Liver Metastasis, Colorectal Cancer
Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)
Despite the advances in the medical treatment of unresectable liver metastases from colorectal cancer there is currently no curative treatment option available for these patients.
- Trial name
- DECIT (NCT02316028)
- Testing
- Decitabine
- Where
- 2 sites in Belgium
- Volunteers
- 11 people
- Sponsor
- Universitair Ziekenhuis Brussel
Colorectal Cancer
Safety and Efficacy Study of Combination Therapy With Cetuximab and FOLFOX4 in Patients With Colorectal Cancer
The purpose of this study is to determine confirmed objective response rate to combination therapy with cetuximab and FOLFOX4 or FOLFOX4 alone in patients with CRC and non-resectable hepatic metastases
- Trial name
- NCT00202787
- Testing
- FOLFOX-4+cetuximab, FOLFOX-4
- Where
- Spain
- Volunteers
- 136 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Colorectal Cancer, Peritoneal Metastases
Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab
The rationale of the current study is that the addition of intraperitoneal irinotecan (75 mg) to palliative systemic therapy is feasible and safe, and might result in an increased overall and progression free survival in patients…
- Trial name
- INTERACT-II (NCT06003998)
- Testing
- Irinotecan, FOLFOX regimen, Bevacizumab
- Where
- 2 sites in Netherlands
- Volunteers
- 85 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
The purpose of the phase 2 component of this study is to determine if giving the immune molecule NPC-1C to individuals who have cancer of the pancreas or gastrointestinal tract (colon or rectum) which has not responded to…
- Trial name
- NCT01040000
- Testing
- NPC-1C/NEO-102
- Where
- 6 sites in United States
- Volunteers
- 94 people
- Sponsor
- Precision Biologics, Inc
Metastatic Cancer, Solid Tumor
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
The primary purpose of this study is to see if Sym024 is safe and tolerable as monotherapy and in combination with Sym021 in patients with solid tumor malignancies.
- Trial name
- NCT04672434
- Testing
- Sym021, Sym024
- Where
- 4 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Symphogen A/S